AWARD NUMBER DAMD17-94-J-4307

TITLE: Genetic Alterations in Familial Breast Cancer: Mapping and Cloning Genes Other Than BRCA1

PRINCIPAL INVESTIGATOR: Mary-Clair King, Ph.D.

CONTRACTING ORGANIZATION: University of California, Berkeley
Berkeley, California 94720

REPORT DATE: September 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
The purpose of this project was to identify genes responsible for inherited predisposition to breast cancer in families. The gene PTEN was successfully cloned by this project, and simultaneously by others (for a different reason) and proved to be such a gene. This project indicated that inherited mutations in PTEN predispose to breast cancer in women with the rare Cowden's syndrome. However, symptoms of that syndrome may be very subtle, so breast cancer may be the first sign to appear. Inherited mutations in PTEN predispose to multiple other cancers that may appear with breast cancer in these patients. Also, this project demonstrated the value of patients with germline translocations and breast cancer for the identification of tumor suppressor genes.
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Principal Investigator's Signature: Mary Claire King
Date: Jan 31, 1998
GENETIC ALTERATIONS IN FAMILIAL BREAST CANCER: MAPPING AND CLONING GENES OTHER THAN BRCA1

TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Front cover</td>
<td>1</td>
</tr>
<tr>
<td>SF298, Report documentation page</td>
<td>2</td>
</tr>
<tr>
<td>Foreword</td>
<td>3</td>
</tr>
<tr>
<td>Table of contents</td>
<td>4</td>
</tr>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Body</td>
<td>7</td>
</tr>
<tr>
<td>Conclusions</td>
<td>20</td>
</tr>
<tr>
<td>References</td>
<td>21</td>
</tr>
</tbody>
</table>
GENETIC ALTERATIONS IN FAMILIAL BREAST CANCER: MAPPING AND CLONING GENES OTHER THAN BRCA1

INTRODUCTION

Despite the importance of BRCA1 and BRCA2 to inherited breast cancer, it is clear that there remain families with multiple cases of breast cancer with no identified BRCA1 or BRCA2 mutations (after screening the entirety of both genes) and no apparent linkage of breast cancer to either 17q21 or 13q12 (see our 1995 progress report; Schubert et al. 1997; Czabo and King 1997). The goal of project DAMD17-94-J4307 was to identify genes responsible for inherited breast cancer in these and other "unexplained" families. In the course of carrying out a genome-wide screen for linkage in these families, it became clear that the frequent combination of late age at breast cancer onset and small family size would limit the statistical power of linkage analysis. Therefore, we decided to integrate linkage analysis with the analysis of germline chromosomal abnormalities that might predispose to breast cancer.

In order to identify germline chromosomal abnormalities that might alter breast cancer genes, we sought patients who had both very early onset breast cancer and developmental abnormalities. It was our hypothesis that this combination of phenotypes would often reflect de novo, germline chromosomal rearrangements in genes critical to breast cancer, as well as of genes critical to normal development. The most promising case discovered so far in this search was that of a young woman (LP) with early bilateral breast cancer in the context of Cowden's syndrome and a complex de novo rearrangement of chromosomes 10q, 2q, and 13q.

Although Cowden disease is rare, it was our hypothesis that the Cowden disease gene might influence breast cancer risk in families other than those with Cowden disease. It is well-documented that some mutations in a gene may lead to a very severe phenotype and other mutations in the same gene to a more restricted phenotype. The high frequency of breast cancer in female Cowden patients (~30%)
makes it a strong candidate for a breast cancer susceptibility gene (Hanssen and Fryns 1995).

Cowden's disease is a multiple hamartoma syndrome with an autosomal dominant pattern of inheritance (Weary et al. 1972), originally described in the family of Rachel Cowden (Lloyd and Dennis 1963). Cowden disease is characterized by multiple nodules of the skin and mucous membranes, fibromas of breast and thyroid, and gastrointestinal polyps (Brownstein et al. 1977). Mental retardation, macrocephaly, seizures, and ataxia are frequently involved. Although Cowden syndrome has traditionally been defined by skin lesions, it also involves cancer of internal organs, most frequently thyroid and breast.

From the outset of this project, we were aware that breast cancer frequently occurs in the context of Cowden's disease (Walton et al. 1986). In seven families with 21 cases of Cowden disease, inheritance was autosomal dominant with high penetrance and high frequency of breast cancer in females, craniomegaly, gastrointestinal polyps, and fibromas (Starink et al. 1986). In another Cowden disease family, the proband had multiple papillomas and was diagnosed at age 32 with breast cancer. Her mother died of breast cancer at age 42, and 2 maternal aunts had premenopausal breast cancer (Williard et al. 1992). In still another large Cowden disease family, there was greater disease severity and earlier onset in successive generations (Hanssen et al. 1993).

Our efforts to clone genes spanning the translocation breakpoints of LP were supported by DAMD17-94-J4307. After the critical gene PTEN was cloned (Li et al. 1997, Steck et al. 1997), we characterized the role of PTEN in inherited predisposition to breast cancer (Lynch et al. 1997; included in this report). This cloning and characterization form the body of this report.
Cloning translocation breakpoints on chromosome 10q

In an effort to clone the gene responsible for Cowden's syndrome, we identified a patient with Cowden's syndrome and an abnormal karyotype. Cytogenetic analysis of LP chromosomes indicated a complex chromosomal rearrangement involving 2q, 10q, and 13q. Following the publication of linkage for Cowden's syndrome to chromosome 10q23-q24 (Nelen et al. 1996), we concentrated molecular analysis on the chromosome 10q breakpoint. STSs for genetic markers flanking and within the Cowden's critical region were used to isolate BAC clones by PCR screening of commercially available DNA pools (Research Genetics, Inc.). A list of BACs identified by this STS screening and their location on the translocated chromosomes is shown in Table 1. These BACs were then used to further characterize the translocation breakpoints, as described below.

Our analysis by fluorescence in situ hybridization (FISH) revealed that LP's chromosome 10q23 breakpoint was within the Cowden's disease region defined by linkage (Table 1). Marker AFMa086wg9 identified BAC 151F15 which by FISH analysis of LP chromosomes was distal to the der10 breakpoint. Marker D10S215 identified BAC 336J2 which by FISH analysis was proximal to the der10 breakpoint. Marker D10S215 also identified BAC 200C8 which by FISH was proximal to the der10 breakpoint and showed a faint signal on the der2 chromosome at 2q33.3. This result was unexpected. The ends of BAC 200C8 were sequenced and PCR primers developed. PCR primers specific to the T7 end of BAC 200C8 were used to screen the BAC DNA pools. BACs 101I13 and 380E3 were positive for BAC 200C8 T7 primers. FISH analysis of B101I13 indicated a strong hybridization signal on the der10q23.3 and on der 2q33.3, confirming the earlier result with BAC 200C8. Fish analysis of BAC 380E3 showed a strong hybridization signal on der 2q33.3 and on der13q14.1. Taken together this data indicates that the patient's chromosome 10q rearrangement involved
chromosomes 2, 10, and 13 and that a submicroscopic portion of chromosome 10 was present on the der2 chromosome at the point of translocation.

PCR primer pair 151F15.SP6, specific to the SP6 end of BAC 151F15, was developed and tested against all other BACs identified in this study. 151F15.SP6 amplified BAC 151F15 and BAC 380E3. Hence we had identified a BAC contig across both chromosome 10 breakpoints from proximal marker D10S215 to distal marker AFMa086wg9 (Table 1).

Table 1. Contig of BACs in Cowden's region of chromosome 10q23.3

<table>
<thead>
<tr>
<th>BACs</th>
<th>336J2</th>
<th>200C8</th>
<th>10113</th>
<th>380E3.</th>
<th>151F15</th>
<th>288D12</th>
<th>328G18</th>
<th>81N3</th>
<th>290C21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimal contig including CD gene</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

D10S215
200C8.T7
151F15.SP6
AFMa086wg9
D10S541
WI-8733
D10S564
position relative to breakpoint on LP chromosome 10
position on LP chromosome der2
proximal proximal proximal proximal distal distal distal distal distal

der2 der2
Candidate genes for Cowden's Disease

To identify genes in this contig, whole BACs 101113 and 380E3 were sonicated and shotgun subcloned into M13mp18. Sample sequencing of these two BACs included 768 individual M13 subclones from BAC 101113 and 480 individual M13 subclones from BAC 380E3. For these two BACs approximately 80% of the inserts contained human sequences, 13% contained E. coli DNA, 5% contained BAC vector DNA only, and 2% contained no insert. The insert sizes for BACs 101113 and 380E3 are 150Kb and 90Kb respectively, as determined by PFGE analysis of NotI digested BAC DNA. The total amount of novel sequence identified for BACs 101113 and 380E3 was 220 kb. Analysis of contigs generated from this sequence indicates that only one contig of sequence is shared between these two BACs. The amount of DNA sequence shared by BACs 101113 and 380E3 is roughly 5 kb. Of the possible 245 kb of genomic sequence, our sample sequencing identified approximately 220 kb which is divided into 93 individual contigs ranging in size from 650 bp to 8.2 kb with an average size of 2 kb.

Chromatograms from M13 subclones of BACs were base-called by Phred, and contigs generated using Phrap (P. Green, unpublished), repetitive elements were masked by RepeatMasker (A. Smit, unpublished), and the subsequent sequence was used to search the non-redundant and EST databases at the NCBI. We developed a program to automate this sequence analysis called "SeqHelp" which generates output in HTML format (Lee et al., in press). The BLAST analysis of BAC sequences revealed numerous EST hits and several hits on the non-redundant database. In the cases where ESTs were identified to share a high degree of sequence similarity with the genomic sequences derived in our lab, that EST or cluster of ESTs was used for an iterated BLAST search and to search against the Unigene database. Where possible, a minimal tiling path of ESTs for a particular gene was identified and those clones were obtained from Research Genetics. Upon arrival, each IMAGE consortium EST was verified by sequencing in the forward and reverse directions. A compilation of ESTs and
genes identified by this sample sequencing strategy is shown in Table 2. In total, this strategy identified one probable pseudogenes, two known genes, and eight novel genes.
Table 2. Clones for Cowden's region.

<table>
<thead>
<tr>
<th>Candidate gene</th>
<th>Contig</th>
<th>EST IMAGE clone</th>
<th>Genbank 5'</th>
<th>Genbank 3'</th>
<th>Library</th>
<th>Size</th>
<th>Rcvd</th>
<th>BAC bin</th>
<th>Repeat</th>
<th>T7 seq</th>
<th>T3 seq</th>
<th>maps</th>
<th>Sthn</th>
<th>blt</th>
<th>cDNA lifts</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>87</td>
<td>yd10e12</td>
<td>66766</td>
<td>T67647</td>
<td>T68418</td>
<td>1NFLS</td>
<td>1400</td>
<td>11.27</td>
<td>1</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>YES</td>
<td>same as yd77112</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>95</td>
<td>yd2211</td>
<td>149517</td>
<td>M00274</td>
<td>900</td>
<td>11.27</td>
<td>1</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>Y</td>
<td>no hits</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>110a</td>
<td>zyb6e04</td>
<td>307065</td>
<td>W21284</td>
<td>none</td>
<td>NbHL19</td>
<td>1528</td>
<td>11.27</td>
<td>1</td>
<td>yes</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>HIT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>110b</td>
<td>yx82e12</td>
<td>221326</td>
<td>H92038</td>
<td>H92039</td>
<td>N2b4-HR</td>
<td>897</td>
<td>11.27</td>
<td>1</td>
<td>yes</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>YES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>110c</td>
<td>yx44e06</td>
<td>264611</td>
<td>N29304</td>
<td>N20238</td>
<td>2Nb4-HR</td>
<td>1521</td>
<td>11.27</td>
<td>1</td>
<td>no</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>HIT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>110d</td>
<td>ze38e04</td>
<td>361374</td>
<td>AA017584</td>
<td>AA017563</td>
<td>N2b4-HR</td>
<td>1200</td>
<td>11.27</td>
<td>1</td>
<td>no</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>YES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>110e</td>
<td>z0f0g12</td>
<td>376274</td>
<td>AA041283</td>
<td>AA040800</td>
<td>NbHL19</td>
<td>450</td>
<td>11.27</td>
<td>1</td>
<td>no</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>similar to MN1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>110f</td>
<td>ze66g12</td>
<td>364006</td>
<td>AA021528</td>
<td>AA021529</td>
<td>N2b4-HR</td>
<td>2100</td>
<td>11.27</td>
<td>1</td>
<td>no</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>similar to auxlin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>110g</td>
<td>z5b0g9</td>
<td>361017</td>
<td>none</td>
<td>AA057423</td>
<td>N2b4-HR</td>
<td>2100</td>
<td>11.27</td>
<td>1</td>
<td>no</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>similar to auxlin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>31</td>
<td>mh88e08</td>
<td>458054</td>
<td>AA028745</td>
<td>none</td>
<td>NbMP13.5</td>
<td>na</td>
<td>1.18</td>
<td>3</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>ND</td>
<td>MSP1 (mouse)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>45</td>
<td>yc38e01</td>
<td>82776</td>
<td>T73612</td>
<td>none</td>
<td>liver</td>
<td>na</td>
<td>1.18</td>
<td>3</td>
<td>X</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>74</td>
<td>yx11a12</td>
<td>214462</td>
<td>H71498</td>
<td>H71499</td>
<td>1NFLS</td>
<td>1040</td>
<td>1.18</td>
<td>1+2</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>88</td>
<td>ys84c09</td>
<td>221486</td>
<td>H92144</td>
<td>none</td>
<td>N2b4-HR</td>
<td>na</td>
<td>1.18</td>
<td>3+2</td>
<td>L1</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>90</td>
<td>yv71d12</td>
<td>257687</td>
<td>N40032</td>
<td>N27294</td>
<td>2Nb4-HR</td>
<td>na</td>
<td>1.18</td>
<td>2</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>111124</td>
<td>T83352</td>
<td>T82265</td>
<td>1NFLS</td>
<td>1.18</td>
<td>2</td>
<td>O</td>
<td>O</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>101</td>
<td>mh89g05</td>
<td>336536</td>
<td>W18519</td>
<td>none</td>
<td>p3NMF19.5</td>
<td>na</td>
<td>1.18</td>
<td>2</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>ATP sulfurylase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>105</td>
<td>yd89a10</td>
<td>268890</td>
<td>N35829</td>
<td>none</td>
<td>2Nb4-HM</td>
<td>na</td>
<td>1.18</td>
<td>1</td>
<td>X</td>
<td>O</td>
<td>N?</td>
<td>colfin (5q13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>117</td>
<td>yf96e02</td>
<td>304665</td>
<td>R18232</td>
<td>R42168</td>
<td>1Nb17EI</td>
<td>1741</td>
<td>1.18</td>
<td>3</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>alpha tubulin (K00558)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1Nb18EI</td>
<td>1741</td>
<td>1.18</td>
<td>3</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>alpha tubulin (K00558)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1Nb18EI</td>
<td>1464</td>
<td>1.18</td>
<td>3</td>
<td>X</td>
<td>X</td>
<td>Y</td>
<td>alpha tubulin (K00558)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1Nb18EI</td>
<td>1785</td>
<td>1.18</td>
<td>3</td>
<td>O</td>
<td>O</td>
<td>?</td>
<td>alpha tubulin (K00558)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1Nb18EI</td>
<td>254372</td>
<td>11.27</td>
<td>1</td>
<td>Flarna</td>
<td>X</td>
<td>X</td>
<td>NO</td>
<td>alpha tubulin (K00558)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- **Table 2. Clones for Cowden's region.**
- Soares libraries in TTT3D: retina (HR), melanocyte (HM), heart (HH19W), liver/spleen (FLS), placenta (HP), lung (HL19W)
- Other libraries: Morton fetal coeloms; Stratagene colon, fetal spleen 937205, liver 937224, lung 937210

**References:**
- Table 2: Clones for Cowden's region.
- Soares libraries in TTT3D: retina (HR), melanocyte (HM), heart (HH19W), liver/spleen (FLS), placenta (HP), lung (HL19W).
Mutations in candidate genes

To search for mutations in candidate genes, we first probed Southern blots of genomic DNA from LP and control individuals. No abnormal restriction patterns or band intensities were observed. Next we evaluated each gene in the region using SSCP to detect small sequence changes. We had collected DNA from 12 different Cowden's families including the translocation patient, all of which were to be examined using SSCP.

During the course of searching for mutations in the candidate genes from Table 2, two reports were published of a putative tyrosine phosphatase, PTEN, on chromosome 10q23 that is deleted in late stage tumors (Li et al. 1997, Steck et al. 1997). This gene corresponds to Candidate Gene 3 of Table 2. Reports of the role of PTEN in cancer, and immediately thereafter in Cowden's syndrome (Nelen et al. 1997), prompted us to look more closely at this gene in our Cowden's syndrome families.

We screened all Cowden's syndrome families by sequencing PTEN exons from genomic DNA. Mutations were identified in seven families which are likely to be the cause of Cowden's syndrome in these patients. We did not identify any PTEN sequence changes or rearrangements in LP. Our characterization of PTEN in families with breast cancer and Cowden's syndrome was published in American Journal of Human Genetics, which is included as the next section of this report.
Inherited Mutations in PTEN That Are Associated with Breast Cancer, Cowden Disease, and Juvenile Polyposis

Eric D. Lynch,1 Elizabeth A. Ostermeyer,1 Ming K. Lee,1 J. Fernando Arena,4 HanLee Ji,1 Jamie Dann,1 Karen Swisshelm,2 David Suchard,3 Patrick M. MacLeod,5 Stener Kvinnsland,6 Bjorn Tore Gjertsen,6,7 Ketil Heimdal,6 Herb Lubs,4,8 Pål Møller,6 and Mary-Claire King1

Departments of 1Medicine and Genetics and 2Pathology and 3Harborview Medical Center, University of Washington, Seattle; 4Department of Pediatrics and Sylvester Comprehensive Cancer Center, University of Miami, Miami; 5Genetics Section, Victoria General Hospital, Victoria, British Columbia; 6Unit of Medical Genetics, Division of Oncology, Norwegian Radium Hospital, Oslo; 7Sogn and Fjordane County Hospital, Forde, Norway; and 8University of Tromsoe, Tromsø, Norway

Summary

PTEN, a protein tyrosine phosphatase with homology to tensin, is a tumor-suppressor gene on chromosome 10q23. Somatic mutations in PTEN occur in multiple tumors, most markedly glioblastomas. Germ-line mutations in PTEN are responsible for Cowden disease (CD), a rare autosomal dominant multiple-hamartoma syndrome. PTEN was sequenced from constitutional DNA from 25 families. Germ-line PTEN mutations were detected in all of five families with both breast cancer and CD, in one family with juvenile polyposis syndrome, and in one of four families with breast and thyroid tumors. In this last case, signs of CD were subtle and were diagnosed only in the context of mutation analysis. PTEN mutations were not detected in 13 families at high risk of breast and/or ovarian cancer. No PTEN-coding-sequence polymorphisms were detected in 70 independent chromosomes. Seven PTEN germ-line mutations occurred, five nonsense and two missense mutations, in six of nine PTEN exons. The wild-type PTEN allele was lost from renal, uterine, breast, and thyroid tumors from a single patient. Loss of PTEN expression was an early event, reflected in loss of the wild-type allele in DNA from normal tissue adjacent to the breast and thyroid tumors. In RNA from normal tissues from three families, mutant transcripts appeared unstable. Germ-line PTEN mutations predispose to breast cancer in association with CD, although the signs of CD may be subtle.

Introduction

The protein tyrosine phosphatase and tensin homologue PTEN is a tumor suppressor of glioblastoma, breast cancer and prostatic cancer (Li and Sun 1997; Li et al. 1997; Steck et al. 1997), and malignant melanoma (Guldberg et al. 1997). The gene has at least three names: “PTEN” (phosphatase with tensin homology; Genbank accession number U93051), “MMAC1” (mutated in multiple advanced cancers; Genbank accession number U92436), and “TEP1” (TGFβ-regulated and epithelial-cell-enriched phosphatase; Genbank accession number U96180). In primary breast carcinomas, both somatic and germ-line PTEN mutations occur, albeit at low frequency (Rhei et al. 1997). Previous observations of loss of heterozygosity (LOH) at chromosome 10q23 in follicular thyroid cancer and endometrial cancers suggested that PTEN might act as a tumor suppressor for these cancers as well (Jones et al. 1994; Zedenius et al. 1995).

In patients with Cowden disease (CD; MIM 158350 [Hanssen and Fryns 1995]), germ-line mutations in PTEN have been identified (Liaw et al. 1997; Nelen et al. 1997). Germ-line PTEN mutations are also associated with the closely related Bannayan-Zonana syndrome (Marsh et al. 1997).

In this report, we evaluate families with inherited predisposition to breast cancer and/or CD or related syndromes, for germ-line mutations in PTEN. We identify and characterize germ-line point mutations in PTEN in seven families, describe the cancer and other phenotypes associated with each of these mutations, and demonstrate somatic loss of the wild-type PTEN allele in the associated tumors.

Subjects and Methods

Family Ascertainment

Twenty-five families were included in this analysis. Five families (families 97, 903, 1085, 1130, and 1163;
Table 1

Phenotypes Associated with Inherited Mutations in PTEN

<table>
<thead>
<tr>
<th>MUTATION(S)</th>
<th>EFFECT</th>
<th>FAMILY</th>
<th>PATIENT (SEX)</th>
<th>Skin Lesions</th>
<th>Breast</th>
<th>Endometrium</th>
<th>Thyroid</th>
<th>CNS</th>
<th>Gastrointestinal Tract</th>
</tr>
</thead>
<tbody>
<tr>
<td>68 T→A</td>
<td>L22X</td>
<td>903</td>
<td>I-2 (F)</td>
<td>+</td>
<td>Ca (46)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>903</td>
<td>II-1 (F)</td>
<td>+</td>
<td>Ca (24)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>328 C→T</td>
<td>Q109X</td>
<td>1130</td>
<td>I-2 (F)</td>
<td>+</td>
<td>Ca (34)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>565 A→T</td>
<td>R188X</td>
<td>1085</td>
<td>I-2 (F)</td>
<td>+</td>
<td>Bil Ca (31)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1085</td>
<td>II-1 (F)</td>
<td>+</td>
<td>Ad (29)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1085</td>
<td>II-2 (F)</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>697 C→T</td>
<td>R232X</td>
<td>97</td>
<td>II-1 (F)</td>
<td>+</td>
<td>Ca (27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1003 C→T</td>
<td>R334X</td>
<td>241</td>
<td>I-1 (M)</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>241</td>
<td>II-2 (M)</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1003 C→T</td>
<td>R334X</td>
<td>227</td>
<td>II-1 (F)</td>
<td>+ DCIS (41)</td>
<td>Ca (42)</td>
<td>Fol Ad (42)</td>
<td></td>
<td></td>
<td>Macro Sm Int Ca (34)</td>
</tr>
<tr>
<td>1028 T→A</td>
<td>V332E</td>
<td>1163</td>
<td>I-2 (F)</td>
<td>+</td>
<td>Ca (50)</td>
<td>Ad (49)</td>
<td>Neu (33, 34)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and</td>
<td></td>
<td>1163</td>
<td>II-2 (F)</td>
<td>+</td>
<td>Ad (30)</td>
<td>Ca (48)</td>
<td>Fol Ad (32, 40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1039 T→C</td>
<td>F346L</td>
<td>1163</td>
<td>II-3 (F)</td>
<td>+ Atyp H (33)</td>
<td>Ca (42)</td>
<td>Fol Ad (33)</td>
<td></td>
<td>Pin (42)</td>
<td>D polyps (31)</td>
</tr>
<tr>
<td>and</td>
<td></td>
<td>1163</td>
<td>II-4 (M)</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1163</td>
<td>II-5 (F)</td>
<td>+</td>
<td>Ca (42)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1163</td>
<td>III-1 (F)</td>
<td>+ Ad (17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note.—Ad = adenoma; Atyp H = atypical hyperplasia; Bil = bilateral; C = colon; Ca = adenocarcinoma; D = duodenal; DCIS = ductal carcinoma in situ; Fol = follicular; G = gastric; Hem = hemangioma; L = liver; Macro = macrocephaly; Neu = malignant neuroma; Nf = neurofibroma; Pap = papillary; Pin = pineal-gland tumor; R = renal cell; and Sm Int = small intestine. A plus sign (+) denotes a chronic condition.

table 1) were ascertained for co-occurrence of breast cancer and CD in the same family. Four other families (including family 227; table 1) were ascertained for co-occurrence of breast and thyroid tumors without definite diagnosis of CD, although the proband of family 227 was subsequently evaluated as having features of the syndrome (table 1). Thirteen families at high risk of breast, ovarian, and/or prostate cancer but with no detected signs of CD were also included. At least one affected member in each of these 13 families had wild-type sequences at BRCA1 and BRCA2; in 2 families, linkage of cancer predisposition to markers flanking PTEN yielded small positive LOD scores (1.3 and 1.2).

Three other families with diagnoses of CD were included. Family 241 (table 1) was diagnosed with both juvenile polyposis syndrome (MIM 174900) and CD. In another CD family, individuals had macrocephaly, skin lesions, and mental retardation but no cancer; in three generations. In a third CD family, affected individuals had thyroid adenomas, intestinal polyps, neurofibromas, lipomas, and colon cancer, at ages 48 and 68 years.

Of the families described above, seven (including 903, 1085, 1130, and 1163) were evaluated clinically at the Norwegian Radium Hospital. Three families (including 227 and 241) were evaluated clinically at the University of Washington hospitals. The other families were from our series of families at high risk of breast and ovarian cancer. Protocols for human subjects were approved by the institutional review boards at the University of Washington, the Norwegian Radium Hospital, and other collaborating institutions, as appropriate.

Lymphoblast cell lines were prepared (Henle and Henle 1970; Raskind et al. 1984), and DNA was extracted from cell lines and from whole blood, by use of a high–salt-extraction method (Gentra Systems).

Genotyping Families and Tumors

Markers D10S583, D10S215, D10S541, D10S573, and D10S564 were used to determine haplotypes for pedigree analysis and for evaluation of LOH in tumors. Primer sequences for these markers are available on-line from the GenBank (http://www.ncbi.nlm.nih.gov/genbank/query_form.html). Markers were typed by use of PCR conditions and electrophoresis protocols described in the work of Friedman et al. (1994).

Dissection of Tumor Blocks

Paraffin-embedded tissue samples were cut into 5-micron sections for staining with hematoxalin and eosin.
Table 2

Primer Pairs That Amplify PTEN cDNA

<table>
<thead>
<tr>
<th>EXONS</th>
<th>Forward</th>
<th>Reverse</th>
<th>ALIGNMENT TO PUBLISHED cDNA SEQUENCES (nt)</th>
<th>SIZE (nt)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5</td>
<td>5'-CCCAGACATGACACCACATCATC-3'</td>
<td>5'-GTGGTGAGGGTTATGGCTTCAAAAGG-3'</td>
<td>U93051 (PTEN) 1-289</td>
<td>1028-1323 296</td>
</tr>
<tr>
<td>4-6</td>
<td>5'-CTGAAAGACATTATGACACCGG-3'</td>
<td>5'-GCTCTCTGGTCTACCCCATAG-3'</td>
<td>U92436 (MMAC) 215-486</td>
<td>1249-1520 272</td>
</tr>
<tr>
<td>5-7</td>
<td>5'-GGAAGGAGGAGAATGTTAATG-3'</td>
<td>5'-AGCTGCAAGCAAAACTGAG-3'</td>
<td>379-659</td>
<td>1413-1693 281</td>
</tr>
<tr>
<td>6 and 7</td>
<td>5'-CAATGTTCAGTGGCCGAACTTG-3'</td>
<td>5'-TTTTCGAGGTTCCTCTGCCAGG-3'</td>
<td>611-866</td>
<td>1645-1900 320</td>
</tr>
<tr>
<td>7-9</td>
<td>5'-CAGTAGTTCTCTCCACAAAGG-3'</td>
<td>5'-CTCCGCTGGACTTGACG-3'</td>
<td>759-1078</td>
<td>1763-2112 356</td>
</tr>
</tbody>
</table>

With the H- and E-stained slide as a guide, normal and tumor cells were microdissected from adjacent 10-micron sections that had also been deparaffinized. Genomic DNA was extracted from the microdissected cells by use of the manufacturer's suggested protocol (Gentra Systems).

Sequencing Genomic DNA, for PTEN Mutations

To analyze patient DNA for mutations in the PTEN gene, nested PCR products corresponding to each of the nine exons were amplified. PCR primers are as described by Steck et al. (1997). PCR products were purified by centrifugation through Sephacryl 300 (Sigma) in 96-well plates (Nalge Nunc International). Purified PCR products were quantified by visual inspection following electrophoresis through 2% agarose gels and ethidium bromide staining. Patient samples were sequenced by use of Energy Transfer Dye Primers (Amersham). The sequencing products were resolved on an ABI377 fluorescent DNA sequencer. Base calling of the trace files was done by use of the ABI sequence-analysis software version 3.0. PTEN-coding sequence and flanking splice junctions were sequenced from 70 independent normal chromosomes.

Transcript Analysis

Isolation of poly(A)⁺ RNA was performed by use of oligo-dT cellulose in a high-salt environment (Sambrook et al. 1989). Patient and control mRNA was reverse transcribed with random hexamers (Amersham) and Superscript Moloney murine leukemia virus RTase (Gibco-BRL), by use of standard procedures. Table 2 indicates the primer pairs used to amplify cDNA, the exons amplified by each pair, and the sizes of amplified products. PCR was performed for 35 cycles, at 94°C for 15 s, 55°C for 15 s, and 72°C for 1 min, and the products were purified by centrifugation through Sephacryl-300 columns (Sigma). Purified PCR products were cycle sequenced by use of dye-terminator chemistry (Perkin Elmer–ABI). Sequencing products were resolved on 4% LongRanger acrylamide gels (FMC), with an ABI-377 fluorescent sequencer.

The existence of a pseudogene similar to PTEN complicates mutation analysis of PTEN cDNA. We used cDNA to evaluate stability of mutant PTEN transcripts but not as the template for original mutation detection. Variants detected in cDNA can be inferred to be from the PTEN gene if they are also observed in genomic DNA amplified with PTEN-specific genomic primers.

Results

Mutations in Families

Mutations in the PTEN-coding sequence were identified in the seven families illustrated in figure 1. All seven mutations involved single-nucleotide substitutions. Six were nonsense mutations leading to immediate stops in exons 1 and 5-8. One variant comprised two missense mutations in exon 9, 1028 T→A (V342I) and 1039 T→C (F346L), on the same parental chromosome. No polymorphisms in the PTEN-coding sequence were detected in any of 70 unrelated chromosomes.

Germ-line mutations in PTEN and their associated phenotypes are indicated in table 1 and figure 1. Multiple invasive cancers occurred in the seven families with germ-line mutations. Among 10 women >30 years of age who had confirmed or probable germ-line mutations, there have been eight breast cancers, three endometrial cancers, one thyroid cancer, one malignant neumora, and one renal-cell carcinoma. Of the two adult men with germ-line mutations, one died of intestinal cancer at age 35 years, and the other was diagnosed with brain cancer at age 42 years.

Nonsense mutation 697 C→T in individual 9701 is de novo. Parentage in family 97 was verified by multiple markers on chromosome 10 (fig. 1). Both parents have wild-type sequence at bp 697 (fig. 2). It is not clear in which parental chromosome the new mutation occurred. Nonsense mutation R232X was observed previously in
Figure 1  Cancers and noninvasive lesions in families with PTEN germ-line mutations. Symbols are divided into segments on the basis of organ site, with blackened quadrants representing cancers and with gray-shaded quadrants representing noninvasive tumors. PTEN mutations are indicated above each family, and the heterozygous variant (VN) or homozygous normal (NN) genotype for each tested individual is shown below the symbol representing that individual. Haplotypes comprising five markers flanking PTEN are shown for families 227 and 241, to demonstrate the independence of the 1003 C->T mutation. PTEN genotypes and marker haplotypes for family 97 indicate that the PTEN mutation in the daughter is de novo.

a CD patient (Liaw et al. 1997) and occurs in a potential tyrosine phosphate-acceptor motif (Steck et al. 1997).

The paired missense mutations in family 1163 occurred in both affected relatives for whom DNA was available. The wild-type transcript was absent, in RNA prepared from whole blood of the affected individuals (fig. 2). Hence the two missense mutations are likely to be on the same chromosome. Mutation 1028 T->A changes the exon 9 splice acceptor from tagGT to tagGA and so may lead to aberrant splicing of this last exon. The instability could be due to the missense mutations or to aberrant splicing.

Nonsense mutation 1003 C->T appeared in both individual 22701 and family 241, as independent mutations. The haplotype constructed from D10S573, D10S215, D10S541, D10S564, and D10S583 in family 241 (fig. 1) shares no alleles with the comparable haplotype in patient 22701. Data from LOH studies of tumor specimens further suggests that allele 7 at D10S541 is on the haplotype with the mutation in patient 22701 (see below).

No germ-line mutations in the PTEN-coding sequence were detected in two families with CD but no early-onset cancers. Nor were germ-line PTEN mutations detected in any of the 13 breast cancer families that have wild-type sequence at BRCA1 and BRCA2. With the screening method that we employed, genomic deletions of an exon or more would not have been detected. However, large deletions do not appear to account for a substantial proportion of germ-line PTEN mutations, although these are common as somatic alterations (Li et al. 1997; Steck et al. 1997).

LOH in Tumors

Biopsy specimens from renal-cell carcinoma, uterine carcinoma, breast ductal carcinoma in situ (DCIS), and thyroid adenoma of patient 22701 were evaluated for
Figure 2  PTEN sequences from genomic DNA (gDNA), tumor DNA, and constitutional cDNA, from families with inherited mutations in this tumor-suppressor gene. Heterozygosity for inherited mutations in genomic DNA is illustrated for probands from seven families. Sequences may be either sense or antisense; mutations are indicated for the sense strand. Sequence “22701-tumor” reflects hemizygosity for the mutant PTEN allele in DNA from the renal-cell carcinoma of patient 22701. Sequences “24101 cDNA,” “1163.1 cDNA,” and “9701 cDNA” reflect the presence of only the wild-type transcript in normal cells from individuals with mutations, consistent with instability of the mutant transcripts. Sequences of genomic DNA from 9702 and 9703, parents of 9701, are homozygous normal, indicating that the mutation in individual 9701 is de novo.

LOH at PTEN bp 1003 and at markers D10S215, D10S541, and D10S564. All tumors revealed both LOH at the three markers and hemizygosity for the mutant allele at the altered site (fig. 2). Loss of the normal allele and retention of the mutant sequence support the hypothesis that PTEN acts as a tumor suppressor. Normal tissue surrounding the renal-cell carcinoma and the uterine carcinoma were heterozygous at bp 1003, as expected. Interestingly, DNA from apparently normal tissue adjacent to the DCIS and adjacent to the thyroid adenoma was clearly hemizygous, retaining only wild-type sequence.

Loss of Mutant Transcripts from Patient mRNA

For families 97, 241, and 1163, cDNA was prepared from lymphoblast poly(A)⁺ RNA, in order to test the stability of mutant and wild-type transcripts. As shown in figure 2, mutant transcripts were not detected in RNA by dye-terminator sequencing. Loss of mutant transcripts from patients with nonsense mutations is consistent with degradation of these transcripts through a nonsense-mediated pathway (Decker and Parker 1994; Maquat 1996).

Discussion

The genetics of germ-line mutations in PTEN is consistent with its somatic genetics and biochemistry, all of which indicate that the gene is a tumor suppressor for breast and other cancers (Li and Sun 1997; Li et al. 1997; Liaw et al. 1997; Steck et al. 1997). The PTEN gene has distinctive features at the levels of cells, families, and species. First, the gene is highly conserved. Human and mouse amino acid sequences are >97% identical (Steck et al. 1997). The gene is also highly conserved within humans.

Second, consequences of even minimal mutations may be profound, even at the level of transcription. Nonsense-mediated mRNA degradation leading to transcript instability has been characterized in several species (Leeds et al. 1991; Pulak and Anderson 1993; Cui et al. 1995). Nonsense-mediated mRNA degradation may
play a role in the reduced mRNA expression of disease-related nonsense mutations (Dunn et al. 1989; Lim et al. 1992; Friedman et al. 1994; Menon and Neufeld 1994). The absence of mutant transcripts in cDNA from affected individuals with PTEN germ-line nonsense mutations suggests that the PTEN mutant transcript may be degraded by a nonsense-mediated pathway.

Third, a high fraction of tumors have deleted the gene and some flanking sequence. The phenotypes associated with either somatic or germ-line mutations are highly variable. In the same person, one germ-line mutation and several somatic mutations may lead to tumors in multiple organ systems. The multiple hamartomas in various organs suggest expression in early development and tissue differentiation. A gene critical to early development could well be highly conserved among species.

Lhermitte-Duclos disease is observed in some families with CD and is associated with severe neurological symptoms (Lhermitte and Duclos 1920; Albrecht et al. 1992). None of the patients with detected PTEN mutations in our series were diagnosed with Lhermitte-Duclos disease. Because mutations in these families were found throughout the gene, and because mutations in families with Lhermitte-Duclos disease have been observed in exons 2 and 5-7 and in intron 4 (Liaw et al. 1997; Nelen et al. 1997), it appears unlikely that mutations causing Lhermitte-Duclos disease cluster in any one region of PTEN.

Fourth, a high proportion of observed mutations are new, rather than persisting over several generations or recurring as founder mutations in individuals who are not closely related. PTEN mutations that were observed in more than one family are independent events. These characteristics may reflect mutation and selection interacting in a particularly dramatic way for an important gene. PTEN may be vulnerable to the entire range of types of mutations, but the gene may be so functionally constrained and so ubiquitously expressed that essentially no alterations are benign.

Acknowledgments

We thank Virginia Sybert, Barbara Trask, Rachel Hernandez, and Piri Welsh for technical advice and helpful discussion. This study was supported in part by a supplement to NIH grant P30-CA14395 to J.F.A.; by memorial contributions from the Mary Gibford family to K.S.; and by NIH grant RO1-CA27632, Department of Defense grant DAMD 17-94-J-4370, and an American Cancer Society Research Professorship to M.-C.K.

References


Li DM, Sun H (1997) TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57:2124-2129


Marsh DJ, Dahia PLM, Zheng Z, Liaw D, Parsons R, Gorlin
CONCLUSIONS

1. Inherited mutations in PTEN/MMAC predispose to breast cancer. These mutations are always in the context of Cowden's Syndrome, and do not appear in families with breast cancer in the absence of Cowden's symptoms. However, the Cowden's symptoms may be very subtle, and breast cancer may be the first manifestation of PTEN mutation to come to clinical notice.

2. Clinicians should consider testing for mutations in PTEN in patients with very young breast cancer, or breast cancer in combination with other malignancies.

3. Breast cancer patients with germline chromosomal translocations offer excellent opportunity to identify other tumor suppressor genes for breast cancer.

4. Still more genes for inherited predisposition to breast cancer probably exist.
REFERENCES


Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King M-C. 1997. BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Amer J Human Genet 60: 1031-1040.


